PMID- 19851718
OWN - NLM
STAT- MEDLINE
DCOM- 20100920
LR  - 20211028
IS  - 1476-3524 (Electronic)
IS  - 1029-8428 (Print)
IS  - 1029-8428 (Linking)
VI  - 18
IP  - 2
DP  - 2010 Aug
TI  - Mice lacking multidrug resistance protein 1a show altered dopaminergic responses 
      to methylenedioxymethamphetamine (MDMA) in striatum.
PG  - 200-9
LID - 10.1007/s12640-009-9124-z [doi]
AB  - Multidrug resistance protein 1a (MDR1a) potentiated methylenedioxymethamphetamine 
      (MDMA)-induced decreases of dopamine (DA) and dopamine transport protein in mouse 
      brain one week after MDMA administration. In the present study, we examined if 
      mdr1a wild-type (mdr1a +/+) and knock-out (mdr1a -/-) mice differentially handle 
      the acute effects of MDMA on the nigrostriatal DA system 0-24 h following a 
      single drug injection. 3-way ANOVA revealed significant 2-way interactions of 
      strain x time (F (5,152) = 32.4, P < 0.001) and strain x dose (F (3,152) = 25.8, 
      P < 0.001) on 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratios in mdr1a +/+ and 
      -/- mice. 0.3-3 h after 10 mg/kg MDMA, DOPAC/DA ratios were increased in mdr1a 
      +/+ mice, but decreased 0.3-1 h after MDMA in mdr1a -/- mice. Twenty-four hours 
      after 10 mg/kg MDMA, DOPAC/DA ratios were increased 600% in mdr1a +/+ mice 
      compared to saline-treated control mice, while in mdr1a -/- mice DOPAC/DA ratios 
      were unchanged. Striatal MDMA and its metabolite, methylenedioxyamphetamine, 
      concentrations by gas chromatography-mass spectrometry were similar in both 
      strains 0.3-4 h after MDMA, discounting the role of MDR1a-facilitated MDMA 
      transport in observed inter-strain differences. Increased DOPAC/DA turnover in 
      mdr1a +/+ mice following MDMA is consistent with the previous report that MDMA 
      neurotoxicity is increased in mdr1a +/+ mice. Increased DA turnover via monoamine 
      oxidase in mdr1a +/+ vs -/- mice might increase exposure to neurotoxic reactive 
      oxygen species.
FAU - Scheidweiler, Karl B
AU  - Scheidweiler KB
AD  - Chemistry and Drug Metabolism, Intramural Research Program, National Institutes 
      of Health, Biomedical Research Center, 251 Bayview Boulevard Suite 200, Room 
      05A-721, Baltimore, MD 21224, USA.
FAU - Ladenheim, Bruce
AU  - Ladenheim B
FAU - Cadet, Jean Lud
AU  - Cadet JL
FAU - Huestis, Marilyn A
AU  - Huestis MA
LA  - eng
GR  - ZIA DA000540-03/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20091023
PL  - United States
TA  - Neurotox Res
JT  - Neurotoxicity research
JID - 100929017
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B, Member 1)
RN  - 102-32-9 (3,4-Dihydroxyphenylacetic Acid)
RN  - 333DO1RDJY (Serotonin)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - 54-16-0 (Hydroxyindoleacetic Acid)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
RN  - X77S6GMS36 (Homovanillic Acid)
SB  - IM
MH  - 3,4-Dihydroxyphenylacetic Acid/metabolism
MH  - 3,4-Methylenedioxyamphetamine/pharmacokinetics
MH  - ATP Binding Cassette Transporter, Subfamily B, Member 1/*genetics
MH  - Animals
MH  - Corpus Striatum/*drug effects/metabolism
MH  - Dopamine/*metabolism
MH  - Homovanillic Acid/metabolism
MH  - Hydroxyindoleacetic Acid/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Mice, Knockout
MH  - N-Methyl-3,4-methylenedioxyamphetamine/pharmacokinetics/*pharmacology
MH  - Serotonin/metabolism
PMC - PMC2917895
MID - NIHMS223884
EDAT- 2009/10/24 06:00
MHDA- 2010/09/21 06:00
PMCR- 2011/08/01
CRDT- 2009/10/24 06:00
PHST- 2009/04/24 00:00 [received]
PHST- 2009/10/07 00:00 [accepted]
PHST- 2009/08/04 00:00 [revised]
PHST- 2009/10/24 06:00 [entrez]
PHST- 2009/10/24 06:00 [pubmed]
PHST- 2010/09/21 06:00 [medline]
PHST- 2011/08/01 00:00 [pmc-release]
AID - 10.1007/s12640-009-9124-z [doi]
PST - ppublish
SO  - Neurotox Res. 2010 Aug;18(2):200-9. doi: 10.1007/s12640-009-9124-z. Epub 2009 Oct 
      23.